Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to -$106.1 million.

  • ARS Pharmaceuticals' Cash from Investing Activities fell 367.46% to -$45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.1 million, marking a year-over-year decrease of 418.49%. This contributed to the annual value of -$106.1 million for FY2024, which is 21.70% down from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash from Investing Activities of -$106.1 million as of FY2024, which was down 21.70% from -$87.2 million recorded in FY2023.
  • ARS Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$55,000 during FY2021, with a 5-year trough of -$106.1 million in FY2024.
  • In the last 3 years, ARS Pharmaceuticals' Cash from Investing Activities had a median value of -$87.2 million in 2023 and averaged -$64.5 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Cash from Investing Activities soared by 94.00% in 2021 and then plummeted by 43,709.05% in 2023.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Cash from Investing Activities stood at -$917,000 in 2020, then skyrocketed by 94.00% to -$55,000 in 2021, then slumped by 261.82% to -$199,000 in 2022, then slumped by 43,709.05% to -$87.2 million in 2023, then decreased by 21.70% to -$106.1 million in 2024.